Cellular Therapies: Revolutionizing Cancer Therapy, Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia

In this second of four videos on the topic of cellular therapies for the hematologic malignancies, Carl H June, MD,  describes the five-step design of CAR T cell therapy, from blood donation to modified T cell infusion, and reviews the phase 1 study of CTL019 (CAR T) therapy in patients with refractory, relapsed chronic lymphocytic leukemia, as well as outcomes for this trial and the characteristics of patients with long term durable remission.

To view other parts of this program:

Part 1: Adoptive Cell Therapy - An Introduction

Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia

Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future

 

 

Related Links

• Clinical Briefing: Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
• Case Study: A 65-year-old male is treated with CD-19 chimeric antigen receptor T-cell therapy for purine-refractory CLL
• Dr. June’s Profile